NASDAQ · Biotechnology

CTNM (CTNM) Stock

$14.16 +2.16% NASDAQ: CTNM Healthcare

Valuation

MetricValue
Price$14.16
Market Cap$529.39M
P/E Ratio-6.62
P/B Ratio2.06
P/S Ratio0.00
EPS (TTM)$0.00
52-Week High$16.70
52-Week Low$3.69
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-22.99%
ROA-21.66%
ROCE-26.05%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.03
Current Ratio26.80

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$50.0M$0$0
Operating Profit$-29.0M$-23.0M$-16.0M$-51.0M$-68.0M
Net Profit$-29.0M$-24.0M$23.0M$-42.0M$-60.0M
EPS$-1.15$-0.97$0.13$-1.63$-2.17
Op Margin——-32.1%——

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$71.0M$51.0M$130.0M$213.0M$277.0M
Total Liabilities$9.0M$11.0M$198.0M$15.0M$16.0M
Cash$5.0M$6.0M$16.0M$22.0M$76.0M
Borrowings$5.0M$6.0M$193.0M$6.0M$8.0M

Latest News

Are You Looking for a Top Momentum Pick? Why Contineum Therapeutics, Inc. (CTNM) is a Great Choice Zacks · Jul 9, 2026 Contineum Therapeutics Publishes Discovery of Potential Best-in-Class LPAR1 Antagonist PIPE-791 in Journal of Medicinal Chemistry Business Wire · Jun 30, 2026 Are Medical Stocks Lagging Adagene (ADAG) This Year? Zacks · Jun 2, 2026 Contineum Therapeutics to Present at the 2026 Goldman Sachs Global Healthcare Conference Business Wire · Jun 1, 2026 Wall Street Analysts See a 59.96% Upside in Contineum Therapeutics, Inc. (CTNM): Can the Stock Really Move This High? Zacks · May 25, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-26.0M$-20.0M$19.0M$-33.0M$-55.0M
Investing Cash Flow$-65.0M$22.0M$-66.0M$-70.0M$-4.0M
Financing Cash Flow$0$0$0$1.0M$0
Net Cash Flow$-11.0M$1.0M$10.0M$6.0M$54.0M
Free Cash Flow$-26.0M$-20.0M$19.0M$-33.0M$-56.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-10.73%
Quick Ratio38.00
Interest Coverage—
Return 1Y161.27%
Return 3Y—
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAPLApple Inc. $313.33 +0.29% 37.72 $4.60T 0.34%
MSFTMicrosoft Corporation $499.99 +0.03% 22.95 $3.71T 0.94%
GOOGLAlphabet Inc. $354.30 -0.96% 27.68 $4.29T 0.23%
AMZNAmazon.com, Inc. $274.48 +0.82% 28.76 $2.95T 0.00%
METAMeta Platforms, Inc. $592.10 +0.37% 21.47 $1.51T 0.35%

About CTNM

CTNM is led by CEO Carmine N. Stengone, employs 41 people, headquartered in US, publicly traded since 2024.

CTNM stock trades at $14.16 with a market capitalization of $529.39M. The stock is valued at a price-to-earnings (P/E) ratio of -6.62, price-to-book of 2.06, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $3.69 and $16.70, and currently trades 15.2% below its 52-week high.

On profitability, CTNM generates a return on equity (ROE) of -22.99%, return on capital employed of -26.05%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides